RE:Investor Presentation has been updated on their website.CAR T therapy targeting solid tumors is restrained by limited infiltration and persistence of those cells in the tumor microenvironment (TME). Dr. RIchard Vile's team at the Mayo Clinic have demonstrated that CAR-T cells loaded with the OV pelareorep followed by a "booster shot" of pelareorep was able to "cure" 100% of the subjects of their solid tumors. ONCY's oncolytic virus pelareorep was able to traffic the CAR-T cells to the tumor site, facilitate in the infilitration of T-cells into the tumor cell, overcome the challenge of an immunosuppressive TME and offer the persistance required for a rigorous immune response required to kill the cancer.